unknown
Stage
About
Zoe Biosciences develops therapies targeting cardiometabolic diseases such as heart failure with preserved ejection fraction (HFpEF), obesity, and sarcopenia by focusing on pathways involving PAI-1 and APJ.
Explore Zoe Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.